FDA Center Backs 160 Premarket Device Authorizations
The Center for Devices and Radiological Health is utilizing real-world evidence to support new medical device approvals.
Updated on Oct. 26, 2026 in Economic Indicators
Live Poll
Do you believe using real-world data in medical device approvals improves the quality of patient care?
The Center for Devices and Radiological Health has now supported more than 160 premarket authorizations using real-world evidence. Officials are highlighting this data-driven approach as a standard for evaluating new medical technologies.
Why it matters
Integrating real-world data allows regulators to evaluate device performance outside of traditional trials. This shift is intended to speed up the approval process for medical innovations while maintaining high safety standards.
The FDA agency has reached a milestone of 160 premarket authorizations supported by real-world evidence. The exact proportion of total device approvals this represents remains under investigation.
The players
Center for Devices and Radiological Health
This FDA agency is responsible for ensuring the safety and effectiveness of medical devices available in the United States.
The details
Regulators are advising developers to verify the relevance and reliability of their data sources early by using Q-Submissions. Companies are also expected to identify and mitigate potential data bias during the initial planning stages of their submissions.
Timeline
October 22, 2026: CDRH officials discussed the implementation and use of real-world evidence.
Macro View
The agency’s increasing reliance on real-world evidence directly follows the implementation goals set by the 21st Century Cures Act. This milestone reflects a broader transition toward using digital and clinical data sets to supplement historical trial models.
This regulatory approach may result in faster access to new medical devices for patients across the United States. Increased use of real-world data can help reduce development costs and timelines, potentially impacting device pricing and availability for healthcare providers.
The takeaway
Developers should prioritize data integrity and bias mitigation early in the Q-Submission process to ensure their applications meet regulatory requirements. Leveraging real-world evidence is becoming a critical component for bringing new medical technologies to market efficiently.
Further reading
For broader context on current regulatory trends, visit the Economic Indicators section.
Source note: This article includes information reported by Insights.
Live Poll
Do you believe using real-world data in medical device approvals improves the quality of patient care?
